Developments in cancer vaccines for hepatocellular carcinoma (Q38533017)

3 September 2017

1 reference

title

Developments in cancer vaccines for hepatocellular carcinoma (English)

1 reference

3 September 2017

1

0 references

author name string

HEPAVAC Consortium

series ordinal

2

1 reference

3 September 2017

publication date

21 June 2015

1 reference

Cancer Immunology, Immunotherapy

3 September 2017

published in

1 reference

3 September 2017

volume

65

1 reference

3 September 2017

issue

1

1 reference

3 September 2017

page(s)

93-99

1 reference

Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Resection and liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Local-Regional Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Sorafenib: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Management of hepatocellular carcinoma: beyond sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Hepatocellular carcinoma pathogenesis: from genes to environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Medical therapies for hepatocellular carcinoma: a critical view of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Antigen-presenting cell function in the tolerogenic liver environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Challenges in cancer vaccine development for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Therapeutic Cancer Vaccines and Translating Vaccinomics Science to the Global Health Clinic: Emerging Applications Toward Proof of Concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

ProPred: prediction of HLA-DR binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Prediction of MHC class I binding peptides using profile motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

MHCPred 2.0: an updated quantitative T-cell epitope prediction server

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-015-1728-Y

10.1007/S00262-015-1728-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1045359177

0 references

1 reference